118 related articles for article (PubMed ID: 19644534)
21. Gastrointestinal stromal tumors: treatment patterns of a population-based sample.
Harlan LC; Eisenstein J; Russell MC; Stevens JL; Cardona K
J Surg Oncol; 2015 May; 111(6):702-7. PubMed ID: 25900896
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
23. [Gastrointestinal stromal tumors: surgical treatment and targeted therapy].
Kanner DY; Kononets PV; Shveikin AO; Shestakov AL
Khirurgiia (Mosk); 2017; (12):28-35. PubMed ID: 29286027
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal stromal tumors: a paradigm for therapeutic options in solid organ tumors.
Novak C; Trevino JG
Mini Rev Med Chem; 2010 Jun; 10(7):624-34. PubMed ID: 20500152
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].
Tong X; Jiang Q; Zhang P; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):907-910. PubMed ID: 32927517
[TBL] [Abstract][Full Text] [Related]
26. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
27. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
28. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
29. [Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].
Cao H; Wang M
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):823-834. PubMed ID: 32927504
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal Stromal Tumors: A Review.
Asija AP; Mejia AV; Prestipino A; Pillai MV
Am J Ther; 2016; 23(2):e550-7. PubMed ID: 23942136
[TBL] [Abstract][Full Text] [Related]
31. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
Gold JS; Dematteo RP
Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K; Berthold DR
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.
Banerjee S; Cunningham D
Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S28-35. PubMed ID: 20630848
[TBL] [Abstract][Full Text] [Related]
34. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
[No Abstract] [Full Text] [Related]
35. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors.
Fukuda K; Saikawa Y; Sako H; Yoshimura Y; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
Oncol Rep; 2013 Jul; 30(1):71-8. PubMed ID: 23619463
[TBL] [Abstract][Full Text] [Related]
37. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
38. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant and neoadjuvant therapy for primary GIST.
Eisenberg BL; Smith KD
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S3-8. PubMed ID: 21116626
[TBL] [Abstract][Full Text] [Related]
40. [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].
Li W; Peng QW; Lin Y; Wan WZ; Zeng XY; Sun X; Yang WC; Xiong Z; Liu WZ; Tao KX; Zhang P
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):896-903. PubMed ID: 32927515
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
